2019
Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
Epperla N, Costa L, Vaughn J, Hanel W, Raya S, Cashen A, Sarmad R, Badar T, Hamadani M, Liu Y, Barta S, Caimi P, Sethi T, Reddy N, Burkart M, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Ballard H, Svoboda J, Emery L, Lansigan F, Glenn M, Churnetski M, Cohen J, Sorge C, Xavier A. Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure. Blood 2019, 134: 1554. DOI: 10.1182/blood-2019-129199.Peer-Reviewed Original ResearchPR/stable diseasePrimary treatment failureClassical Hodgkin lymphomaAnthracycline-containing chemotherapy regimensOutcomes of patientsHigh-dose chemotherapyStable diseaseOverall survivalER cohortComplete remissionSeattle GeneticsSpeakers bureauPP cohortSalvage therapyChemotherapy regimensProgressive diseasePartial responseTreatment failureHodgkin's lymphomaNew agentsAdvanced-stage classical Hodgkin lymphomaFive-year overall survivalRelapsed classical Hodgkin lymphomaAutologous hematopoietic cell transplantationRefractory classical Hodgkin lymphoma
2016
Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma
Sethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma. Therapeutic Advances In Hematology 2016, 8: 13-20. PMID: 28042455, PMCID: PMC5167078, DOI: 10.1177/2040620716676256.Peer-Reviewed Original ResearchProgression-free survivalNodular sclerosis Hodgkin lymphomaSyncytial variantOverall survivalHodgkin's lymphomaSV patientsComplete responseSV groupShorter progression-free survivalMedian overall survivalOutcomes of patientsPoor-risk groupLower CR rateInstitutional review board approvalKaplan-Meier methodSmall case seriesLog-rank testClassical HL patientsReview board approvalAdvanced diseaseInduction regimenAdult patientsClinical characteristicsHL patientsAggressive courseDifferences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL
Sethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL. Clinical Lymphoma Myeloma & Leukemia 2016, 16: s68-s69. DOI: 10.1016/j.clml.2016.07.100.Peer-Reviewed Original Research
2015
Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL
Sethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL. Blood 2015, 126: 1441. DOI: 10.1182/blood.v126.23.1441.1441.Peer-Reviewed Original ResearchNodular sclerosis Hodgkin lymphomaProgression-free survivalOutcomes of patientsAdvanced stage diseaseOverall survivalComplete responseHodgkin's lymphomaB symptomsStage diseaseSV groupAchievement of CRInferior progression-free survivalMedian progression-free survivalHodgkin/Reed-Sternberg cellsInstitutional IRB approvalMedian overall survivalStandard ABVD chemotherapyStandard salvage regimensHigh-dose therapyKaplan-Meier methodOnly independent predictorStem cell transplantStage of diseaseCompletion of treatmentNew immunomodulatory agents